skip to Main Content
large burst
light ray
upper burst
square

Unlock the
power of proteins

Apply our revolutionary CodeEvolver® platform technology to deliver high-performing enzymes and customized solutions in a wide array of applications.

Watch the video
blue-dna

Pharmaceuticals

Improve production processes with state-of-the-art enzymes.

Learn More

adam-staring-at-petri-dish

Biotherapeutics

Create novel therapeutic proteins with highly optimized performance.

Learn More

Sugar_enzyme

Food & Beverage

Impact product quality and profitability with expert protein engineering.

Learn More

molecular-diagnostics-thumb

Molecular Diagnostics

Accelerate next-generation sequencing with powerful enzyme solutions.

Learn More

blockquote

“We chose the Codexis platform after a thorough evaluation of the enzyme evolution landscape. Codexis has a significant track record of delivering evolved biocatalysts for pharmaceutical and fine chemical applications over an extended period of time.”

Doug Fuerst, Technology Development Lead, Synthetic Biology
GlaxoSmithKline

“[Codexis’] process, which won a 2010 Presidential Green Chemistry Award, increased sitagliptin yield, cut back on production steps, and reduced water use and waste. The advance led to a threefold increase in productivity and helped us avoid the cost of building a second factory to meet rising demand for Januvia.”

R.P. "Skip" Volante, Vice President of R&D
Merck

“We view Codexis as an extension of our internal research and development programs at Tate & Lyle and are excited about the opportunities which this partnership brings to deliver new and innovative food ingredients to the market.”

Michael Harrison, Senior Vice President of New Product Development
Tate & Lyle

“The partnership with Codexis strengthens our footprint in the enzyme field, a fast-developing part of the nutritional therapy innovation frontier that is changing the way we manage our health.”

Greg Behar, CEO
Nestlé Health Science

Latest News

07May 13

Codexis Reports First Quarter 2013 Results

— Product gross margin increases to 38%; Product revenue up 34% from fourth quarter 2012 — — Conference call today at 4:30 pm ET — REDWOOD CITY, Calif.–(BUSINESS WIRE)–May. 7, 2013– Codexis, Inc. (NASDAQ: CDXS), a developer of…
read more
22Apr 13

Codexis to Present at 2013 BIO International Convention

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Apr. 22, 2013– Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, announced today that Gjalt Huisman, Ph.D., Vice President, Pharmaceutical R&D at Codexis, will present at the 2013…
read more
27Feb 13

Codexis Reports Fourth Quarter and Full Year 2012 Results

— Conference call today at 4:30 pm ET — REDWOOD CITY, Calif.–(BUSINESS WIRE)–Feb. 27, 2013– Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, today announced financial results for the fourth quarter…
read more
Back To Top
Close search
Search